• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺滤泡细胞肿瘤的分类:来自一家机构的日本患者分析。

Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute.

作者信息

Kakudo Kennichi, Bai Yanhua, Katayama Shoichi, Hirokawa Mitsuyoshi, Ito Yasuhiro, Miyauchi Akira, Kuma Kanji

机构信息

Department of Human Pathology, Wakayama Medical University, Wakayama, Japan.

出版信息

Pathol Int. 2009 Jun;59(6):359-67. doi: 10.1111/j.1440-1827.2009.02378.x.

DOI:10.1111/j.1440-1827.2009.02378.x
PMID:19490465
Abstract

Prognostic analyses of thyroid carcinomas of follicular cell origin were carried out on patients treated at Kuma Hospital, Kobe, Japan. A new histopathological classification based on the prognostic evidence is proposed in this study, and it is applicable to the patients treated curatively. Major histological types of papillary carcinoma, follicular carcinoma and poorly differentiated carcinoma were combined into one single entity of follicular cell adenocarcinoma because (i) they have the same cell origin (follicular cell); (ii) clear-cut separation of papillary and follicular carcinoma is not always possible, and 10 year cause-specific survival was essentially similar when the patients were treated curatively; and (iii) poorly differentiated carcinoma usually has a background of either papillary or follicular carcinoma. This adenocarcinoma together with undifferentiated carcinoma was stratified into four prognostic groups using pure morphological criteria of the degree of cellular differentiation and histological grade. They are termed well-differentiated adenocarcinoma, moderately differentiated adenocarcinoma, poorly differentiated carcinoma and undifferentiated carcinoma of the thyroid. The 10 year disease-free survival rates were 86.3-93.1%, 65.4-78.7%, and 43.0-53.8%, and 0%, respectively. The 10 year cause-specific survival rates were 97.2-100%, 91.5-97.4%, and 71.2-80.0%, and 0%, respectively.

摘要

对在日本神户熊本医院接受治疗的滤泡细胞源性甲状腺癌患者进行了预后分析。本研究基于预后证据提出了一种新的组织病理学分类方法,该方法适用于接受根治性治疗的患者。乳头状癌、滤泡状癌和低分化癌的主要组织学类型被合并为滤泡细胞腺癌这一单一实体,原因如下:(i)它们具有相同的细胞起源(滤泡细胞);(ii)乳头状癌和滤泡状癌并非总能明确区分,且接受根治性治疗的患者10年病因特异性生存率基本相似;(iii)低分化癌通常具有乳头状癌或滤泡状癌的背景。利用细胞分化程度和组织学分级的纯形态学标准,将这种腺癌与未分化癌分为四个预后组。它们分别被称为甲状腺高分化腺癌、中分化腺癌、低分化癌和未分化癌。10年无病生存率分别为86.3% - 93.1%、65.4% - 78.7%、43.0% - 53.8%和0%。10年病因特异性生存率分别为97.2% - 100%、91.5% - 97.4%、71.2% - 80.0%和0%。

相似文献

1
Classification of follicular cell tumors of the thyroid gland: analysis involving Japanese patients from one institute.甲状腺滤泡细胞肿瘤的分类:来自一家机构的日本患者分析。
Pathol Int. 2009 Jun;59(6):359-67. doi: 10.1111/j.1440-1827.2009.02378.x.
2
Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience.甲状腺低分化癌的定义:日本的经验
Endocr Pathol. 2004 Winter;15(4):307-11. doi: 10.1385/ep:15:4:307.
3
Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories.p27KIP1 的下调以及 Ki67/Mib1 标记指数支持将甲状腺癌分类为具有预后相关性的类别。
Am J Surg Pathol. 1999 Jun;23(6):678-85. doi: 10.1097/00000478-199906000-00007.
4
Overview of the 2022 WHO Classification of Thyroid Neoplasms.2022 年世卫组织甲状腺肿瘤分类概述。
Endocr Pathol. 2022 Mar;33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14.
5
Insular carcinomas of the thyroid exhibit poor prognosis and long-term survival in comparison to follicular and papillary T4 carcinomas.与滤泡性和乳头状T4甲状腺癌相比,甲状腺岛状癌的预后较差,长期生存率较低。
Langenbecks Arch Surg. 2007 Nov;392(6):671-7. doi: 10.1007/s00423-006-0122-9. Epub 2007 Jan 10.
6
Prognostic value of the 8 tumor-node-metastasis classification for follicular carcinoma and poorly differentiated carcinoma of the thyroid in Japan.日本甲状腺滤泡癌和低分化癌的8版肿瘤-淋巴结-转移分类的预后价值
Endocr J. 2018 Jun 27;65(6):621-627. doi: 10.1507/endocrj.EJ17-0524. Epub 2018 Apr 4.
7
Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.
Thyroid. 2007 Jul;17(7):639-46. doi: 10.1089/thy.2007.0029.
8
Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.乳头状和滤泡状甲状腺癌的病理肿瘤-淋巴结-转移(pTNM)分期:700例患者的回顾性分析
J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62. doi: 10.1210/jcem.82.11.4373.
9
Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland.岛状癌:甲状腺滤泡癌中一种独特的原发实体。
Am J Surg Pathol. 1997 Dec;21(12):1466-73. doi: 10.1097/00000478-199712000-00009.
10
Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination.
World J Surg. 2007 Jul;31(7):1417-24. doi: 10.1007/s00268-007-9095-2.

引用本文的文献

1
Adjuvant External Beam Radiotherapy Reduces Local Recurrence in Poorly Differentiated Thyroid Cancer : A Multicenter Retrospective Cohort Study Describing Outcomes in the Treatment of Resectable Poorly Differentiated Thyroid Cancer.辅助性外照射放疗可降低低分化甲状腺癌的局部复发率:一项多中心回顾性队列研究,描述可切除性低分化甲状腺癌的治疗结果
Ann Surg Oncol. 2025 May 23. doi: 10.1245/s10434-025-17434-2.
2
Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.滤泡细胞来源的甲状腺癌的侵袭性变异型:概述。
Endocrine. 2022 Oct;78(1):1-12. doi: 10.1007/s12020-022-03146-0. Epub 2022 Jul 21.
3
Poorly Differentiated Thyroid Carcinoma: Single Centre Experience and Review of the Literature.
低分化甲状腺癌:单中心经验及文献综述
J Clin Med. 2021 Nov 12;10(22):5258. doi: 10.3390/jcm10225258.
4
Precursor and borderline lesions of the thyroid (indolent lesions of epithelial origin): from theory to practice.甲状腺的前驱病变和交界性病变(上皮源性惰性病变):从理论到实践
Gland Surg. 2020 Oct;9(5):1724-1734. doi: 10.21037/gs-20-429.
5
Histopathology and immunohistochemistry as prognostic factors for poorly differentiated thyroid cancer in a series of Polish patients.波兰患者系列中低分化甲状腺癌的组织病理学和免疫组织化学预后因素。
PLoS One. 2020 Feb 24;15(2):e0229264. doi: 10.1371/journal.pone.0229264. eCollection 2020.
6
Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.索拉非尼治疗碘难治性分化型甲状腺癌患者的临床病理特征与预后相关:一项真实世界研究。
Oncologist. 2020 Apr;25(4):e668-e678. doi: 10.1634/theoncologist.2019-0633. Epub 2020 Jan 20.
7
Active surveillance for young patients with insular thyroid cancer: an initial and novel finding.对岛叶甲状腺癌年轻患者的主动监测:一项初步且新颖的发现。
Am J Transl Res. 2019 Jan 15;11(1):176-187. eCollection 2019.
8
Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference?低分化甲状腺癌及分化型甲状腺癌中的低分化区域:有差异吗?
Langenbecks Arch Surg. 2019 Feb;404(1):45-53. doi: 10.1007/s00423-019-01753-6. Epub 2019 Jan 23.
9
Encapsulated Papillary Thyroid Tumor with Delicate Nuclear Changes and a KRAS Mutation as a Possible Novel Subtype of Borderline Tumor.具有细微核改变及KRAS突变的包膜性甲状腺乳头状肿瘤,可能为一种新型的交界性肿瘤亚型
J Pathol Transl Med. 2019 Mar;53(2):136-141. doi: 10.4132/jptm.2018.12.07. Epub 2019 Jan 14.
10
How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules.甲状腺结节患者管理中如何处理临界性/前驱性甲状腺肿瘤。
Gland Surg. 2018 Aug;7(Suppl 1):S8-S18. doi: 10.21037/gs.2017.08.02.